Sonia Fox

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Claire Harrison, Adam J. Mead, Anesh Panchal et al. · Blood · 2017 · 167 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Claire Harrison, Jyoti Nangalia, Rebecca H. Boucher et al. · Journal of Clinical Oncology · 2023 · 142 citations · Full text

Medicine, Hematology, Pharmacology +8

The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease

Niamh Appleby, Toby A. Eyre, Maité Cabes et al. · BMC Cancer · 2019 · 32 citations · Full text

Medicine, Hematology, Oncology +17

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Talha Munir, Louise-Rae Cherrill, Nichola Webster et al. · Blood · 2022 · 14 citations

Medicine, Immunology, Oncology +4